There is conflicting evidence on the prognostic role of EGFR mutations; while earlier studies found no differences in prognosis between EGFR wild-type and EGFR-mutant cases, advances in EGFR-targeting tyrosine kinase inhibition have led to improved survival in patients whose tumor harbors an EGFR alteration [54]. This evidence concerns the gene EGFR and neoplasm.